Boston Scientific Offers $25 Bil. To Nab Guidant From J&J

Convinced that Johnson & Johnson is undervaluing Guidant, Boston Scientific made an offer of $25 bil. for the cardiovascular device firm on Dec. 5 - approximately $3 bil. more than J&J has agreed to pay